TR199900842A2 - Sübstitüe edilmis trisiklik bilesikler. - Google Patents

Sübstitüe edilmis trisiklik bilesikler.

Info

Publication number
TR199900842A2
TR199900842A2 TR1999/00842A TR9900842A TR199900842A2 TR 199900842 A2 TR199900842 A2 TR 199900842A2 TR 1999/00842 A TR1999/00842 A TR 1999/00842A TR 9900842 A TR9900842 A TR 9900842A TR 199900842 A2 TR199900842 A2 TR 199900842A2
Authority
TR
Turkey
Prior art keywords
ikler
edilmi
bstit
tricyclic
bile
Prior art date
Application number
TR1999/00842A
Other languages
English (en)
Inventor
James Bach Nicholas
Anne Bastian Jolie
Wade Beight Douglas
Dean Kinnick Michael
John Martinelli Michael
David Mihelich Edward
Michael Morin John
Jon Sall Daniel
Scott Sawyer Jason
C.R. Smith Edward
Suarez Tulio
Wang Qiuping
Michael Wilson Thomas
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of TR199900842A2 publication Critical patent/TR199900842A2/tr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/58[b]- or [c]-condensed
    • C07D209/70[b]- or [c]-condensed containing carbocyclic rings other than six-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)

Abstract

Yeni bir trisiklikler sinifi yani sira bu gibi bilesiklerin, septik sok gibi durumlari tedavi etmek üzere, sPLA2 araciligi ile meydana gelen yag asidi tahliyesini engellemek için kullanimlari açiklanmistir.
TR1999/00842A 1998-04-17 1999-04-16 Sübstitüe edilmis trisiklik bilesikler. TR199900842A2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6216598A 1998-04-17 1998-04-17

Publications (1)

Publication Number Publication Date
TR199900842A2 true TR199900842A2 (tr) 2000-09-21

Family

ID=22040624

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1999/00842A TR199900842A2 (tr) 1998-04-17 1999-04-16 Sübstitüe edilmis trisiklik bilesikler.

Country Status (27)

Country Link
EP (2) EP1156050B1 (tr)
JP (1) JP4435325B2 (tr)
KR (1) KR19990083234A (tr)
CN (1) CN1235968A (tr)
AR (1) AR018185A1 (tr)
AT (2) ATE254128T1 (tr)
AU (1) AU757454B2 (tr)
BR (1) BR9901275A (tr)
CA (1) CA2269256A1 (tr)
CO (1) CO5080728A1 (tr)
CZ (1) CZ137199A3 (tr)
DE (2) DE69914951T2 (tr)
EA (1) EA003129B1 (tr)
ES (2) ES2210979T3 (tr)
HU (1) HUP9901219A1 (tr)
ID (1) ID23219A (tr)
IL (1) IL129484A0 (tr)
NO (1) NO991823L (tr)
NZ (1) NZ335252A (tr)
PE (1) PE20000472A1 (tr)
PL (1) PL332564A1 (tr)
SG (1) SG106035A1 (tr)
SV (1) SV1999000052A (tr)
TR (1) TR199900842A2 (tr)
TW (1) TW555760B (tr)
YU (1) YU19099A (tr)
ZA (1) ZA992773B (tr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1011670A4 (en) * 1997-08-28 2004-10-27 Lilly Co Eli PROCESS FOR TREATING NON-RHUMATOID POLYARTHRITIS
WO2001074817A1 (fr) * 2000-03-30 2001-10-11 Yamanouchi Pharmaceutical Co., Ltd. Derives d'hydrazide
WO2002005796A2 (en) * 2000-07-14 2002-01-24 Eli Lilly And Company Use of a spla2 inhibitor for the treatment of sepsis
ATE329905T1 (de) * 2000-12-18 2006-07-15 Lilly Co Eli Tetracyclische derivate als spla2 inhibitoren
JP2004525154A (ja) * 2001-03-28 2004-08-19 イーライ・リリー・アンド・カンパニー sPLA2インヒビターとしての置換カルバゾール
WO2003014082A1 (en) * 2001-08-09 2003-02-20 Eli Lilly And Company Cyclopenta ` b ! indole derivatives as spla2 inhibitors
WO2003016277A1 (en) * 2001-08-09 2003-02-27 Eli Lilly And Company Cyclohept`b!indole derivatives as spla2 inhibitors
US6992100B2 (en) 2001-12-06 2006-01-31 Eli Lilly And Company sPLA2 inhibitors
US7608626B2 (en) 2004-11-01 2009-10-27 Wyeth Substituted indolizines and derivatives as CNS agents
AU2009204048B2 (en) 2008-01-11 2013-08-01 Albany Molecular Research, Inc. (1-azinone) -substituted pyridoindoles as MCH antagonists
WO2011003021A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
US8993765B2 (en) 2010-12-21 2015-03-31 Albany Molecular Research, Inc. Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof
EP2697223B1 (en) * 2011-04-14 2016-07-13 Actelion Pharmaceuticals Ltd. 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators
DK2825541T3 (en) 2012-03-16 2016-10-03 Vitae Pharmaceuticals Inc LIVER-X-receptor modulators
BR112014022780A8 (pt) 2012-03-16 2021-06-15 Vitae Pharmaceuticals Inc composto modulador de receptor de fígado x, composição farmacêutica que o compreende e seu uso

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3979391A (en) * 1972-11-22 1976-09-07 Sterling Drug Inc. 1,2,3,4-Tetrahydrocarbazoles
PT95692A (pt) * 1989-10-27 1991-09-13 American Home Prod Processo para a preparacao de derivados de acidos indole-,indeno-,piranoindole- e tetra-hidrocarbazole-alcanoicos, ou quais sao uteis como inibidores de pla2 e da lipoxigenase
IL109311A0 (en) * 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
IL109309A (en) * 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
WO1996003383A1 (en) * 1994-07-21 1996-02-08 Eli Lilly And Company INDOLIZINE sPLA2 INHIBITORS
ATE203744T1 (de) * 1995-12-13 2001-08-15 Lilly Co Eli Naphthyl-acetamide als spla2-inhibitoren
JP2001503055A (ja) * 1996-10-30 2001-03-06 イーライ・リリー・アンド・カンパニー 置換三環化合物群
JP2001517707A (ja) * 1997-09-26 2001-10-09 イーライ・リリー・アンド・カンパニー 嚢胞性繊維症の処置方法
CA2310250A1 (en) * 1997-11-14 1999-05-27 August Masaru Watanabe Treatment for alzheimer's disease

Also Published As

Publication number Publication date
CA2269256A1 (en) 1999-10-17
HU9901219D0 (en) 1999-06-28
PL332564A1 (en) 1999-10-25
ATE259818T1 (de) 2004-03-15
ID23219A (id) 2000-03-30
BR9901275A (pt) 2000-05-02
ES2213668T3 (es) 2004-09-01
KR19990083234A (ko) 1999-11-25
EP1156050B1 (en) 2004-02-18
HUP9901219A1 (hu) 2000-08-28
AR018185A1 (es) 2001-10-31
TW555760B (en) 2003-10-01
EP0950661B1 (en) 2003-11-12
DE69912670T2 (de) 2004-08-12
YU19099A (sh) 2001-09-28
NO991823L (no) 1999-10-18
EP0950661A1 (en) 1999-10-20
NZ335252A (en) 2000-11-24
EA199900304A2 (ru) 1999-10-28
CO5080728A1 (es) 2001-09-25
EP1156050A2 (en) 2001-11-21
DE69914951T2 (de) 2004-12-23
DE69912670D1 (de) 2003-12-18
EA199900304A3 (ru) 2000-04-24
EA003129B1 (ru) 2003-02-27
PE20000472A1 (es) 2000-06-02
JP4435325B2 (ja) 2010-03-17
AU757454B2 (en) 2003-02-20
CN1235968A (zh) 1999-11-24
EP1156050A3 (en) 2001-11-28
ES2210979T3 (es) 2004-07-01
CZ137199A3 (cs) 1999-11-17
AU2381899A (en) 1999-10-28
IL129484A0 (en) 2000-02-29
JPH11322745A (ja) 1999-11-24
DE69914951D1 (de) 2004-03-25
SV1999000052A (es) 2000-03-14
ATE254128T1 (de) 2003-11-15
NO991823D0 (no) 1999-04-16
ZA992773B (en) 2002-07-16
SG106035A1 (en) 2004-09-30

Similar Documents

Publication Publication Date Title
TR199900853A2 (tr) Sübstitüe edilmis trisiklik bilesikler.
TR199900956T2 (tr) Sübstitüe edilmis trisiklik bilesimler.
TR199900842A2 (tr) Sübstitüe edilmis trisiklik bilesikler.
GT199900055A (es) Nuevas dihidropirimidinas2 heterocìclicamente sustituidas.
BR9917179B1 (pt) processo para gerar um composto de bromo oxidante estÁvel.
SE9903594L (sv) Katjoniska polymerer för slamavvattning
DK1485359T3 (da) Natriumkanalblokkere
TR200000782T2 (tr) Resorsinol türevleri.
ATE457970T1 (de) Zusammensetzungen zur beseitigung von unangenehmen gerüchen
DK0640592T3 (da) N-acylerede tricycliske azaheteroringe anvendelige som vasopressin-antagonister
ATE311206T1 (de) Substituierte porphyrine
ES2055424T3 (es) Derivados de n-fenilbenzamida con actividad anti-ulcera y anti-alergia y un metodo para su preparacion.
GT199900011A (es) Nuevos derivados del acido dihidroxihexanoico
ES2183340T3 (es) Procedimiento para la preparcion de compuestos de 4-bromometil-bifenilo.
TR199801866A1 (tr) Yeni piperazin ve piperidin bilesikleri
TR200001472T2 (tr) 8-metoksi-kuinolon-karboksilik asitlerin hazırlanması için yöntem
ES2210733T5 (es) Compuesto detergente.
ES2159347T3 (es) Naftil-acetamidas como inhibidores de spla2.
TR199800543A2 (tr) Benziloksi ikame edilen, aniliye edilmis N-heterosiklik bilesikler.
FR2379581A1 (fr) Colorants fluorescents derives de la coumarine
PT1067966E (pt) Composicao oftalmica compreendendo um bloqueador beta
TR200102742T2 (tr) Rezorsinol türevleri
ES2136782T3 (es) Procedimiento para producir compuestos de acido quinolin-2-il-benzoico.
CO5160271A1 (es) Composicion de alta pureza que comprende (7 alfa, 17 alfa)- 17-hidroxi-7-metil-19-nor-17-pregn-5(10)-en-20-in-3-ona
ES2174034T3 (es) Naftilglioxamidas como inhibidores de spla2